Two brands can spend the same amount on digital advertising in the same therapeutic area and end up with completely different levels of visibility. One shows up everywhere the target audience actually looks. The other's budget gets absorbed by underperforming placements, weak creative, or channels the audience barely uses. Spend was identical. Share of voice wasn't.
That gap is why share of voice and share of spend measure two different things, even though pharma teams sometimes use them interchangeably.
Share of voice is the percentage of total category visibility a brand actually owns among its target audience: how much of the promotional conversation, in a defined channel and time period, belongs to your brand versus competitors. Share of spend is a modeled estimate of how much a brand and its competitors are spending. One measures what happened. The other estimates what was paid for.
What Share of Voice Means in Pharma
Share of voice isn't a pharma-specific concept. It comes out of general advertising research, and one of the most cited findings behind it comes from marketing effectiveness researchers Les Binet and Peter Field, whose analysis of 171 campaigns between 1980 and 2010 found that brands with excess share of voice, meaning a share of voice higher than their existing market share, tended to gain roughly 0.5 percentage points of market share for every 10 points of excess share of voice (Nielsen). The relationship isn't unique to pharma, but the underlying logic holds here too: brands that are more visible than their current position would predict tend to grow into that visibility over time.
Applied to pharma, share of voice usually means the share of digital impressions, ad placements, and content visibility a brand earns among its target HCP or patient audience, relative to every other brand competing for that same audience's attention in the same channels.
Share of Voice vs. Share of Spend: Why They Diverge
Share of spend is useful as a planning input. It's not a measurement of outcome, because it's typically modeled from aggregated market data rather than observed directly. Two brands can show identical modeled spend and still land in very different places on actual share of voice, for a few reasons:
Channel efficiency varies. A brand that spends the same dollar amount but places it on higher-traffic, more relevant sites will earn more real visibility than a brand spending the same amount inefficiently.
Creative cut-through varies. Impressions served aren't the same as impressions noticed. A weaker creative can buy the same number of placements and still earn a smaller share of actual attention.
Modeled estimates miss channels. Spend models are typically built from a subset of tracked channels. A competitor spending heavily on a channel outside that model's coverage will show up as under-spending when it isn't.
This is the practical reason share of voice tends to be the more useful benchmark: it reflects what the audience was actually exposed to, not what a model assumes a brand paid to reach them.
How to Calculate Digital Share of Voice
The basic formula is straightforward:
Digital Share of Voice = (Your brand's verified digital impressions) / (Total tracked digital impressions across all competing brands) × 100
The formula is simple. What makes the number trustworthy is what goes into it. If the impression counts on either side of that equation come from a modeled spend estimate, the resulting share of voice figure inherits the same blind spots as the estimate itself: aggregated, lagging, and blind to any channel the model doesn't cover. If the impression counts come from verified exposure, meaning real HCPs or patients who were confirmed to have seen the content, the resulting share of voice reflects actual competitive standing rather than a projection of it.
That distinction matters more in pharma than in most categories, because the audience is narrow and specific. A brand can look strong in a broad, modeled estimate and still be nearly invisible to the actual oncologists or rheumatologists it's trying to reach.
Why Digital Share of Voice Matters More Than It Used To
Pharma's channel mix has gotten more fragmented, which makes share of voice harder to estimate accurately and more valuable to measure correctly. Digital now spans paid search, banner ads on both endemic and non-endemic sites, manufacturer and third-party email, social, and increasingly, how a brand is represented in AI-generated answers. A share of voice figure that only accounts for two or three of those channels is missing a growing share of where the real competition is happening.
There's a related metric worth understanding alongside share of voice: share of attention, which ZoomRx has also studied directly. In a Digital Tracker analysis of roughly 600 oncologists and oncology nurse practitioners, physicians exposed to a brand across two or more digital channels showed more than double the share of attention, over 6.7%, compared to physicians exposed through a single channel, at 2.8%, a pattern that held across six oncology indications (ZoomRx). Share of voice measures how much of the competitive conversation a brand owns. Share of attention measures how much of the audience's own research time it earns back. They're different metrics, but they move together, and a brand with low digital share of voice will typically struggle on the attention side too.
What Real Share of Voice Tracking Requires
Calculating an honest share of voice figure depends entirely on having verified impression data across every channel that matters, not a partial or modeled view of a few of them. Digital Tracker builds this from passive observation of verified HCP and patient panelists across banner ads, paid search, email, social, web browsing, and Med AI platforms, capturing over 45,000 healthcare webpage visits and 1,150+ hours of verified browsing time every month from a confirmed target audience rather than a modeled sample. That gives brand teams a share of voice figure built from what actually happened in market, not from an estimate of what competitors likely spent to be there.
Putting Share of Voice to Work
Pre-launch, share of voice benchmarking shows where incumbents and emerging competitors already dominate the conversation, which is useful for setting a realistic media plan rather than assuming a new entrant starts from zero. Post-launch, tracking share of voice on a recurring cadence surfaces competitive shifts early: a sudden jump in a competitor's share of voice ahead of a label update or new indication is a signal worth acting on before it shows up in prescribing data months later.
Used this way, share of voice stops being a retrospective scorecard and becomes an early input into media planning, the same way share of attention functions as a leading indicator of where physician interest is heading before it shows up in Rx data.
Curious what your own digital share of voice actually looks like? Get in touch and we'll show you.
Frequently Asked Questions
